Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{02183c0fb4734a5ea8ade6ed74499f0e,
title = "Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease",
abstract = "AIMS: To evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end-stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD.METHODS AND RESULTS: From Danish nationwide registries, we identified all patients with new-onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5-year absolute risk of HF at several follow-up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen-Johansen estimator was used to account for censoring and the competing risk of death. A total of 285 024 patients with new-onset T2D were included. During follow-up, 19 960 developed incident HF. Among patients with T2D free of HF 5 years after T2D diagnosis, patients without IHD and ESRD had the lowest 5-year risk of HF [4.02{\%}; 95{\%} confidence interval (CI) 3.90-4.15), those with T2D complicated by IHD [11.51{\%}; relative risk (RR) 2.86; 95{\%} CI 2.72-3.02; P < 0.001] or ESRD (8.11{\%}; RR 2.02; 95{\%} CI 1.39-2.93; P < 0.001) an intermediate risk, and those with both IHD and ESRD (19.76{\%}; RR 4.92; 95{\%} CI 3.43-7.05; P < 0.001) the highest risk.CONCLUSION: Patients with T2D complicated by development of intercurrent IHD, ESRD, or both, showed a significantly higher risk of HF compared to those who did not develop IHD and ESRD. An effective way to delay or prevent the development of HF in patients with T2D may be to prevent IHD and ESRD.",
keywords = "End-stage renal disease, Epidemiology, Heart failure, Type 2 diabetes",
author = "Malik, {Mariam E} and Christian Madelaire and Maria D'Souza and Paul Blanche and Kristensen, {S{\o}ren L} and Caroline Kistorp and Finn Gustafsson and Lars K{\o}ber and Rasmus R{\o}rth and John McMurray and Naveed Sattar and Gunnar Gislason and Christian Torp-Pedersen and Morten Schou",
note = "{\circledC} 2020 European Society of Cardiology.",
year = "2020",
month = "5",
doi = "10.1002/ejhf.1819",
language = "English",
volume = "22",
pages = "813--820",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Wiley",
number = "5",

}

RIS

TY - JOUR

T1 - Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease

AU - Malik, Mariam E

AU - Madelaire, Christian

AU - D'Souza, Maria

AU - Blanche, Paul

AU - Kristensen, Søren L

AU - Kistorp, Caroline

AU - Gustafsson, Finn

AU - Køber, Lars

AU - Rørth, Rasmus

AU - McMurray, John

AU - Sattar, Naveed

AU - Gislason, Gunnar

AU - Torp-Pedersen, Christian

AU - Schou, Morten

N1 - © 2020 European Society of Cardiology.

PY - 2020/5

Y1 - 2020/5

N2 - AIMS: To evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end-stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD.METHODS AND RESULTS: From Danish nationwide registries, we identified all patients with new-onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5-year absolute risk of HF at several follow-up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen-Johansen estimator was used to account for censoring and the competing risk of death. A total of 285 024 patients with new-onset T2D were included. During follow-up, 19 960 developed incident HF. Among patients with T2D free of HF 5 years after T2D diagnosis, patients without IHD and ESRD had the lowest 5-year risk of HF [4.02%; 95% confidence interval (CI) 3.90-4.15), those with T2D complicated by IHD [11.51%; relative risk (RR) 2.86; 95% CI 2.72-3.02; P < 0.001] or ESRD (8.11%; RR 2.02; 95% CI 1.39-2.93; P < 0.001) an intermediate risk, and those with both IHD and ESRD (19.76%; RR 4.92; 95% CI 3.43-7.05; P < 0.001) the highest risk.CONCLUSION: Patients with T2D complicated by development of intercurrent IHD, ESRD, or both, showed a significantly higher risk of HF compared to those who did not develop IHD and ESRD. An effective way to delay or prevent the development of HF in patients with T2D may be to prevent IHD and ESRD.

AB - AIMS: To evaluate the risk of heart failure (HF) in patients with type 2 diabetes (T2D) complicated by development of intercurrent ischaemic heart disease (IHD), end-stage renal disease (ESRD), or both, compared to patients with T2D and no IHD and ESRD.METHODS AND RESULTS: From Danish nationwide registries, we identified all patients with new-onset T2D with no history of HF between 1998 and 2015. Landmark analyses were used to estimate the 5-year absolute risk of HF at several follow-up times, and accounted for the occurrence of IHD and ESRD, identified before HF. The Aalen-Johansen estimator was used to account for censoring and the competing risk of death. A total of 285 024 patients with new-onset T2D were included. During follow-up, 19 960 developed incident HF. Among patients with T2D free of HF 5 years after T2D diagnosis, patients without IHD and ESRD had the lowest 5-year risk of HF [4.02%; 95% confidence interval (CI) 3.90-4.15), those with T2D complicated by IHD [11.51%; relative risk (RR) 2.86; 95% CI 2.72-3.02; P < 0.001] or ESRD (8.11%; RR 2.02; 95% CI 1.39-2.93; P < 0.001) an intermediate risk, and those with both IHD and ESRD (19.76%; RR 4.92; 95% CI 3.43-7.05; P < 0.001) the highest risk.CONCLUSION: Patients with T2D complicated by development of intercurrent IHD, ESRD, or both, showed a significantly higher risk of HF compared to those who did not develop IHD and ESRD. An effective way to delay or prevent the development of HF in patients with T2D may be to prevent IHD and ESRD.

KW - End-stage renal disease

KW - Epidemiology

KW - Heart failure

KW - Type 2 diabetes

U2 - 10.1002/ejhf.1819

DO - 10.1002/ejhf.1819

M3 - Journal article

VL - 22

SP - 813

EP - 820

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 5

ER -

ID: 59663772